Tonix Pharmaceuticals Files 8-K on Sept 30, 2025
Ticker: TNXP · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K on 9/30/25 covering disclosures and financials.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on September 30, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Tamandare Explorations Inc., is incorporated in Nevada and headquartered in Chatham, New Jersey.
Why It Matters
This filing provides an update on Tonix Pharmaceuticals' corporate activities and financial reporting, which is crucial for investors to assess the company's current status and compliance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- Tamandare Explorations Inc. (company) — Former company name
- September 30, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Chatham, New Jersey (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing?
The 8-K filing on September 30, 2025, serves as a Current Report for Tonix Pharmaceuticals Holding Corp., covering a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this 8-K filing was on September 30, 2025.
What was Tonix Pharmaceuticals Holding Corp. formerly known as?
Tonix Pharmaceuticals Holding Corp. was formerly known as TAMANDARE EXPLORATIONS INC., with a date of name change on March 20, 2008.
In which state is Tonix Pharmaceuticals Holding Corp. incorporated?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.
What is the principal executive office address for Tonix Pharmaceuticals Holding Corp.?
The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey, 07928.
Filing Stats: 827 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2025-09-30 08:36:03
Key Financial Figures
- $1,860 — treatment of fibromyalgia in adults of $1,860 per month for the 60-count supply. For
- $930 — ith mild hepatic impairment, the WAC is $930 per month for the 30-count supply. For
Filing Documents
- tnxp-8k_093025.htm (8-K) — 25KB
- ex99-01.htm (EX-99.01) — 22KB
- tnxp_001.jpg (GRAPHIC) — 5KB
- 0001999371-25-014216.txt ( ) — 224KB
- tnxp-20250930.xsd (EX-101.SCH) — 3KB
- tnxp-20250930_lab.xml (EX-101.LAB) — 33KB
- tnxp-20250930_pre.xml (EX-101.PRE) — 22KB
- tnxp-8k_093025_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On September 30, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29, 2025. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On September 30, 2025, the Company announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29, 2025. The Company set a wholesale acquisition cost ("WAC") for Tonmya for the treatment of fibromyalgia in adults of $1,860 per month for the 60-count supply. For geriatric patients and adult patients with mild hepatic impairment, the WAC is $930 per month for the 30-count supply.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, September 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: September 30, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer